Vertex Pharmaceuticals, a cystic fibrosis powerhouse, is sprinting into new medical territories with big ambitions. The ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals has announced a colossal $4 billion share buyback plan, building on an existing $775 million repurchase authorization. This turbocharges their total repurchase firepower to ...

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including ...

Vertex raised the low-end of its revenue guidance range for the year ... and their inclusion on this site does not imply any form of partnership, agency, or endorsement. We sell different types ...

Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion versus estimates of $11.97 billion. Get stock picks, daily rankings, and pro-level trading tools in ...

The top-line gains were primarily driven by its cystic-fibrosis drug, which is known as Trikafta in the U.S., and an early contribution form ... Vertex raised the low-end of its revenue guidance ...

Google updated the documentation for the Google-Extended user agent, which publishers can use to control whether Google Gemini and Vertex use their data for training purposes or for grounding AI ...

Google Cloud’s latest enhancements to Vertex AI and the Gemini model family ... a step in the right direction for supporting the wide range of enterprise AI requirements. Early adopters report ...

At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor ...

Vertex’s CF product revenues rose in the double-digit range for 10 consecutive years. In 2024, Vertex’s revenues rose 12% year over year, driven by the continued strong performance and demand ...

Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis ...